IPTACOPAN ASH UPDATE

Iptacopan monotherapy achieved clinically meaningful increases in hemoglobin levels in treatment-naive patients with PNH APPOINT-PNH met primary endpoint of proportion of patients achieving a sustained increase in Hb of ≥ 2g/dL, in the absence of transfusions, at 24 weeks Safety profile consistent with previously reported data Data to be presented at upcoming medical meeting 22 IPTACOPAN ASH UPDATE | DECEMBER 13, 2022 NOVARTIS | Reimagining Medicine

View entire presentation